F.A. KHABIROV^1,2, E.F. RAKHMATULLINA¹, L.R. KADYROVA^1,2, O.S. KOCHERGINA¹, D.Kh. KHAYBULLINA¹

¹Kazan State Medical Academy, 36 Butlerov St., Kazan, Russian Federation, 420012

²Rebublican Clinical Neurology Center, 13 Vatutin St., Kazan, Russian Federation, 420012

Khabirov F.A. — D. Med. Sc., Professor of the Department of Neurology and Manual Therapy, tel. (843) 278-88-29, e-mail: rkbvl@i-set.ru

Rakhmatullina E.F. — Cand. Med. Sc., Associate Professor of the Department of Neurology and Manual Therapy, tel. (843) 278-88-29, e-mail: elsa2109@mail.ru

Kadyrova L.R. — Cand. Med. Sc., Associate Professor of the Department of Neurology and Manual Therapy, tel. (843) 278-88-29, e-mail: lidakad@gmail.com

Kochergina O.S. — Cand. Med. Sc., Associate Professor of the Department of Neurology and Manual Therapy, tel. (843) 278-88-29, e-mail: rkbvl@i-set.ru

Khaybullina D.H. — Cand. Med. Sc., Associate Professor of the Department of Neurology and Manual Therapy, tel. (843) 278-88-29, e-mail: dina.khaibullina@mail.ru

Efficacy of the cartilage protector in complex therapy of scapulohumeral periarthritis of vertebrogenic origin was studied. It was found that the application of cartilage protector for the treatment of this pathology has a positive impact on functional state of the periarticular musculotendinous structures. It was clinically presented as a rapid pin regression and increase of range of motion in the joints.

Key words: scapulohumeral joint, cartilage protector, pain.

REFERENCES

1. Astapenko M.G., Eryalis P.S. Vnesustavnye zabolevaniya myagkikh tkaney oporno-dvigatel’nogo apparata [Extra-articular soft tissue diseases of the musculoskeletal system]. Moscow: Meditsina, 1975. 150 p.
2. Walch G., Noel E., Boulahia A. Rheumatology in Europe, 1999, 28 (4), pp. 129-36.
3. Shirokov V.A. Bol’ v pleche: patogenez, diagnostika, lechenie [Shoulder pain: pathogenesis, diagnosis, treatment]. Ekaterinburg: Izdatel’stvo AMB, 2011. 284 p.
4. Khaybullina D.Kh., Rakhmatullina E.F., Maksimov Yu.N., Kadyrova L.R., Khaybullin T.I., Kochergina O.S Bolevye sindromy plechevogo poyasa: klinika, diagnostika, lechenie. Uchebnoe posobie [Pain syndromes of the shoulder girdle: clinical features, diagnosis, treatment. Textbook]. Kazan, 2013. 38 p.
5. Gubeev Yu.E., Khaybullina D.Kh., Maksimov Yu.N., Esin R.G., Rakhmatullina E.F., Kochergina O.S Vertebrogennye zabolevaniya nervnoy sistemy v detskom i podrostkovom vozraste. Uchebnoe posobie [Vertebrogenic nervous system diseases in childhood and adolescence. Textbook]. Kazan, 2014. 48 p.
6. Khabirov F.A., Khabirova Yu.F. Bol’ v shee i spine: rukovodstvo dlya vrachey [Pain in the neck and back: a guide for physicians]. Kazan: Meditsina, 2014. 504 p.
7. Rakhmatullina E.F., Khabirov F.A., Kochergina O.S. Vozmozhnosti MR-tomografii v diagnostike koksoperiartroza, obuslovlennogo vertebrogennnoy patologiey. Tez. dokl. mezhdunarodnoy konferentsii: Magnitnyy rezonans v meditsine [Possibilities of MRI in the diagnosis koksoperiartroza due vertebrogennnoy pathology. Proc. rep. International Conference: Magnetic Resonance in Medicine]. Kazan, 1997. P. 108.
8. Rakhmatullina E.F. Klinicheskie varianty vertebrogennogo koksoperiartroza: dis. … k. m. n. [Clinical variants vertebrogenic koksoperiartroza. Dis. PhD med. sciences]. Kazan, 1998. 150 p.
9. Ermak E.M. Sovremennye ul’trazvukovye tekhnologii v diagnostike destruktivnykh i reparativnykh protsessov v kostnoy i khryashchevoy tkanyakh: dis. … d-ra med. nauk [Modern ultrasound technology in the diagnosis of destructive and reparative processes in bone and cartilage tissues. Dis. Dr med. sci.]. Chelyabinsk, 2005. 235 p.
10. Bucsi L., Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarth Cart, 1998, 6 suppl A, pp. 39-46.
11. Campo G.M., Avenoso A., Campo S. et al. Chondroitin sulfate: antioxidant properties and beneficial efftects. Mini Rev. Med. Chem, 2006, vol. 6 (12), pp. 1311-1320.
12. Anikin S.G., Alekseeva L.I. Chondroitin Sulfate: mechanisms of action, efficacy and safety in the treatment of osteoarthritis. Sovremennaya revmatologiya, 2012, no. 3 (in Russ.).
13. Nikishchenkova A.S., Zhulev S.N., Zhulev N.M., Ovsyannikova N.A. Artradol (chondroitin sulfate) in the treatment of degenerative disc disease and spinal spondyloarthrosis. Nevrologiya/revmatologiya. Prilozhenie Consilium Medicum, 2012, no. 2 (in Russ.).
14. Imada K., Oka H., Kawasaki D. et al. Anti–arthritic action mechanism of natural chondroitin sulfate in human articular chondrocytes and synovial fibroblasts. Pharm. Bull, 2010, vol. 33 (3), rr. 210-214.
15. Volpi N. Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. Pharm. Pharmacol, 2009, vol. 61 (10), rr. 1271-1280.
16. Zotkin E.G., Shkireeva S.Yu. Features of patients with osteoarthritis in primary care. RMZh, 2012, no. 27 (in Russ.).
17. Ronca F., Palmieri L., Panicucci P. et al. Anti–inflammatory activity of chondroitin sulfate.Cartil, 1998, vol. 6 (suppl. A), rr. 14-21.
18. Legendre F., Bauge C., Roche R. et al. Chondroitin sulfate modulation of matrix and inflammatory gene expression in IL–1betastimulated chondrocytes–study in hypoxic alginate bead cultures. Osteoarthr. Cartil, 2008, vol. 16 (1), rr. 105-114.
19. Wang L., Wang J., Almqvist K.F. et al. Influence of polysulphated polysaccharides and hydrocortisone on the extracellular matrix metabolism of human articular chondrocytes in vitro. Exp. Rheum, 2002, vol. 20 (5), rr. 669-676.
20. Verbruggen G., Veys E.M. Influence of sulphatedglycosaminoglycans upon proteoglycan metabolism of the synovial lining cells. Acta Rhum. Belg, 1977, vol. 1 (12), rr. 75-92.
21. Largo R., Roman-Blas J.A., Moreno–Rubio J. et al. Chondroitin sulfate improves synovitis in rabbits with chronic antigeninduced arthritis. Cartil, 2010, vol. 18 (suppl. 1), rr. 17-23.
22. Pelletier J.P., Martel–Pelletier J., Abramson S.B. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Rheum, 2001, vol. 44 (6), rr. 1237-1247.
23. Nolzmann J., Brandl N., Zemann A. et al. Assorted effects of TGFbeta and chondroitin sulfate on p38 and ERK1/2 activation levels in human articular chondrocytes stimulated with LPS.Cartil, 2006, vol. 14, rr. 519-525.
24. Chou M.M., Vergnolle N., McDougall J.J. et al. Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin–1beta, matrix metalloprotease–9, and cartilage damage in arthritis. Biol. Med. (Maywood), 2005, vol. 230 (4), rr. 255-262.
25. Monfort J., Nacher M., Montell E. et al. Chondroitin sulfate and Hyaluronic acid (500–730 kDa) inhibit stromelysin–1 synthesis in human osteoarthritic chondrocytes. Drugs Exp. Clin. Res, 2005, vol. 31, rr. 71-76.
26. Campo G.M., Avenoso A., Campo S. et al. Glycosaminoglycans modulate inflammation and apoptosis in LPS–treated chondrocytes. Cell Biochem, 2009, vol. 106 (1), rr. 83-92.
27. Caraglia M., Beninati S.D., Alessandro A.M. et al. Alternative therapy of earth elements increases the chondroprotective effects of chondroitin sulfate in mice. Mol. Med, 2005, vol. 37, rr. 476-481.
28. Jomphe C., Gabriac M., Hale T.M. et al. Chondroitin sulfate inhibits the nuclear translocation of nuclear factor–kappa B in interleukin–1beta–stimulated chondrocytes. Basic Clin. Pharmacol. Toxicol, 2008, vol. 102, rr. 59-65.
29. Clegg D.O., Reda D.J., Harris C.L., et al. (February 2006). «Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis». Engl. J. Med, 354 (8), pp. 795-808. doi:10.1056/NEJMoa052771. PMID 16495392.
30. Rozendaal R.M., Koes B.W., van Osch G.J., et al. (February 2008). Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Intern. Med, 148 (4), pp. 268-77. PMID 18283204.
31. Simon Wandel, Peter Jüni, Britta Tendal, Eveline Nüesch Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis (angl.). BMJ Publishing Group Ltd. (5.07.2010).
32. Bourgeois F., Chales C., Delais J., Delcambre B., Kuntz J.L., Rozenber S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3×400 mg / day vs placebo. Cart, 1998, 6 suppl A, pp. 25-30.
33. Leeb B.F. et al. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis.Rheumatol, 2000, Jan, 27 (1), pp. 205-11.
34. Morreale P., Manopulo R., Galati M., Boccanera L., Saponati G., Bocchi L. Comparison of the anti-inflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Rheumatol, 1996, 23, pp. 1385-91.
35. Pavelka K., Bucsi L., Manopulo R. Double-blind, dose effect study of oral CS 4&6 1200 mg, 800 mg, 200 mg against placebo in the treatment of femoro-tibial osteoarthritis. Litera Rheumatol, 1998, 24, pp. 21-30.
36. Uebelhart D. et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage, 2004, Apr, 12 (4), pp. 269-76.
37. Uebelhart D., Thonar E.J.M.A., Delmas P.D., Chantraine A., Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Cart, 1998, 6 supp A, pp. 39-46.